Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Disclaimer. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. All Rights Reserved. losed Joint Stock Company FinTech Solutions, Fidelity NASDAQ Composite Index Tracking Stock Fund, Abbvie stock price analysis: Past year performance, Abbvie fundamental analysis: Q1 2022 earnings, Abbvie stock forecast: Company guidance and analysts predictions. That makes companies like AbbVie generally very attractive to investors although it should be noted that AbbVie carries a very high level of debt which stood at >$60bn as of Q322 - more or less the amount the company paid to acquire Allergan. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. In February, a Phase 3 induction study saw positive top-line results. Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The dividend payout ratio of AbbVie is 89.56%. AbbVie's stock was trading at $161.61 on January 1st, 2023. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. The pharma industry witnessed solid growth amid the pandemic. And never invest or trade money you cannot afford to lose. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. Get daily stock ideas from top-performing Wall Street analysts. Date. The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. This suggests a possible upside of 3.2% from the stock's current price. If you have an ad-blocker enabled you may be blocked from proceeding. GSK Free Cash Flow Forecast for 2023 - 2025 - 2030. As of 2023 February 22, Wednesday current price of ABBV stock is 151.340$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Abbvie stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. Furthermore, it seems sales of Lupron and Synthroid have joined the "All Other" section, which has generated $2.2bn of revenues in the first half of 2022, versus $1.5bn in the first half of 2021. The analysts 12-month consensus ABBV stock price target was $159.75. Always do your own research on a stocks price performance and predictions before making an investment. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. Richard A. Gonzalez has an approval rating of 88% among the company's employees. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. The company's average rating score is 2.44, and is based on 7 buy ratings, 9 hold ratings, and no sell ratings. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. AbbVie's Dividend and Valuation. Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. Let's begin our analysis with the immunology division. PEG Ratios above 1 indicate that a company could be overvalued. Bhd., AbbVie Sp. AbbVie saw a increase in short interest in February. There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. Identify stocks that meet your criteria using seven unique stock screeners. What is AbbVie's stock price forecast for 2023? AbbVie has 5 focus areas for its research and products. AbbVie Inc. is a US-based biopharma company with global operations. Forecasts shouldnt be used as a substitute for your own research. Based on an average daily volume of 5,600,000 shares, the days-to-cover ratio is currently 2.1 days. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. RHHBY vs. ABBV: Which Stock Is the Better Value Option? Refer to our. Payout ratios above 75% are not desirable because they may not be sustainable. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. With Skyrizi and Rinviq - two assets developed in-house - performing so well, however, perhaps we should give management the benefit of the doubt. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. I write about Biotech, Pharma and Healthcare stocks and share investment tips. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Within the oncology division sales of Imbruvica fell 17% year-on-year. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. Read the conference call transcript. We now expect global sales for Skyrizi to reach more than $10 billion in 2025, an increase of $2.5 billion versus our previous guidance, reflecting higher performance across basically all of the indications. AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. AbbVie projected sales - immunology (my forecasts and assumptions). Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. 164.71 0.00 0.00%. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%. 1 dividend stock for a LIFETIME of income. Kateryna Onyshchuk/iStock via Getty Images. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. In the past I have written about the high level of competition between major Pharma in the auto-immune space - for example, for Psoriatic Arthritis the list of approved drugs includes Humira, UCB Pharma's Cimzia, Amgen's Enbrel, Johnson & Johnson's (JNJ) Stelara, Eli Lilly's (LLY) Talzt, Novartis' (NVS) Cosentyx and Bristol-Myers Squibb's (BMY) Orencia. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. AbbVie is a leader in ESG and sustainability. To see all exchange delays and terms of use please see Barchart's disclaimer. We expect that to happen in 2027 with continued significant growth anticipated in the following years. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. (844) 978-6257. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . And it couldnt be more wrong! Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. According to the Abbvie stock technical analysis, as of 30 June, the Relative Strength Index (RSI) was pointing to neutral at 62.18. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. This could present more profit potential for drugmakers as well as investors. As a result I have dropped Imbruvica revenues to just over $3.5bn in 2022 and modelled for a CAGR growth of just 1.5% between then and 2030. All rights reserved. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! The shining star in the aesthetics business is Botox, which increased sales by 45% year over year to $477 million in the first quarter of 2021.